127407-54-9

Upstream product

• 79069-15-1 tert-butyl N-[(1S)-1-(benzyloxymethyl)-2-hydroxy-ethyl]carbamate 
• 124-63-0 methanesulfonyl chloride 
• 80963-10-6 methyl O-benzyl-N-(tert-butoxycarbonyl)-L-serinate 
• 66866-45-3 C₂₀H₂₉NO₇ 
• 23680-31-1 BOC-O-benzyl-L-serine 
• 79069-15-1 N-(tert-butyloxycarbonyl)-O-benzyl-L-serinol 

Downstream Products

• 167421-97-8 1-benzyloxy-2(S)-t-butoxycarbonylamino-3-ethylthiopropane 
• 178761-50-7 3-aza-5-amino-1-(R)-benzyloxymethyl-1-(t-butoxycarbonylamino)pentane 
• 126301-34-6 (S)-2-amino-3-benzyloxypropanesulphonic acid 
• 126301-25-5 (S)-2-amino-3-benzyloxypropyl methanesulphonate hydrochloride 
• 153782-99-1 ((S)-2-Benzyloxy-1-chloromethyl-ethyl)-carbamic acid tert-butyl ester 
• 79069-13-9 (R)-2-tertbutoxycarbonylamino-1-propanol 
• 178761-57-4 (R)-N¹-(2-Amino-ethyl)-3-benzyloxy-propane-1,2-diamine 

Relevant academic research and scientific papers

GLUCOSYLCERAMIDE SYNTHASE INHIBITORS

The present invention comprises glucosylceramide synthase (GCS) inhibitors of structural formula (I), and pharmaceutically acceptable salts thereof, wherein R1, E, A, L, X1, Q, R4, R5, m and n, are as defined he

ETHER DERIVATIVE

The present invention relates to an ether derivative represented by the formula (I), a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof wherein each symbol is as defined in the description, and an ether derivative represented by the formula (III), a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof wherein each symbol is as defined in the description; a pharmaceutical composition containing the ether derivative; and a package containing the pharmaceutical composition and a description of use thereof. A pharmaceutical composition of the present invention, which contains this compound of the present invention has a superior anti-inflammatory and analgesic activity and is useful as various pharmaceutical agents such as an anti-inflammatory agent, an analgesic, a therapeutic agent for inflammatory bowel disease, a therapeutic agent for pollakiuria and/or incontinentia, a therapeutic agent for asthma and the like.

Synthesis of enantiomerically pure 1-(R)- and 1-(S)-hydroxymethyl-DTPA penta-t-butyl esters via chiral aminoalcohols

A convenient synthesis of enantiomerically enriched 1-hydroxymethyl-DTPA (diethylenetriamine pentaacetic acid) penta-t-butyl esters 3 has been achieved for the preparation of chiral synthones of new paramagnetic gadolinium complexes.

Conversion of chiral amino acids to enantiomerically pure α-methylamines

Enantiomerically enriched α-methylamines are obtained in high yield by Raney nickel reduction of N-Boc-protected, amino acid-derived thioethers.

Syntheses and Properties of Optically Active 2-Substituted Taurines

The synthesis of nine 2-substituted taurines (5a-i), including the marine natural product D-cysteinolic acid (5f), are described.These involve the successive conversion of N-t-butoxycarbonyl(Boc)-protected amino acid esters (1) into the N-Boc-2-aminoethanols (2), their O-mesylated derivatives (3), the deprotected 2-aminoethyl methanesulphonates (4), followed by the replacement of the mesyloxy group by a sulpho group to give the optically active taurines (5a-e,g-i).Hydrogenolysis of 2-benzyloxymethyltaurine (5e) gives D-cysteinolic acid (5f).The structure of another of the products, (5b), is also confirmed by an alternative synthesis from N-Boc-valine methyl ester (1b) via twoβ-bromoethylamine derivatives, (6b) and (7b).